Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.

The ability to genetically modify human T cells to target tumor antigens through retroviral gene transfer constitutes a potentially powerful approach to cancer immunotherapy. However, low transduction efficiencies may hamper the efficacy of such therapeutic strategies in the clinical setting. Most commonly, gammaretroviral gene transfer into T cells is conducted through spinoculation, that is, centrifugation of retroviral particles and T cells on RetroNectin-coated non-tissue culture vessels. Here we present data investigating the impact of temperature, speed, and frequency of spinoculation on T cell transduction efficiencies. We found that all three variables independently impacted gene transfer, with increasing temperature, speed, and frequency of spinoculation all enhancing the transduction of T cells. These improved conditions were additive, with the greatest proportion of transduced T cells being generated at the highest tested temperature and speed, after daily spinoculation for 2 to 3 days. Under these conditions, enhanced gene transfer was observed in T cells derived from healthy donors, using research-grade vector stocks. Whereas both RetroNectin and spinoculation were critical to optimal gene transduction, preloading of gammaretroviral particles before spinoculation did not enhance gene transfer. Significantly, application of these enhanced transduction conditions to T cells derived from previously treated patients with chronic lymphocytic leukemia allowed for adequate gene transfer under both small-scale and large-scale clinically applicable conditions using either preclinical or current Good Manufacturing Practice-grade gammaretroviral vector stocks.

[1]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[2]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[3]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[4]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[5]  A. Zander,et al.  Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  D. Klatzmann,et al.  Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. , 2000, Human gene therapy.

[7]  A. Zander,et al.  Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements , 1999, Gene Therapy.

[8]  David A. Williams,et al.  High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes Is Mediated by Transduction on Recombinant Fibronectin Fragments , 1998, Journal of Virology.

[9]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[10]  R. Mulligan,et al.  A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  David A. Williams,et al.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells , 1996, Nature Medicine.

[12]  S. Rosenberg,et al.  T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years , 1995, Science.

[13]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[14]  R. Morgan,et al.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Mulligan,et al.  Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Anderson,et al.  Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. , 1993, Journal of immunology.

[17]  K. Cornetta,et al.  Lymphocytes as cellular vehicles for gene therapy in mouse and man. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[19]  W. Anderson,et al.  Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent , 1989, Journal of virology.

[20]  M. Sadelain,et al.  Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories , 2006, Gene Therapy.

[21]  S. Sleijfer,et al.  Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. , 2006, Cytotherapy.

[22]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.

[23]  J. Segovia,et al.  Systematic analysis of clinically applicable conditions leading to a high efficiency of transduction and transgene expression in human T cells , 2001, The journal of gene medicine.

[24]  M. Yamada,et al.  Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. , 1998, Blood.

[25]  W F Anderson,et al.  Improved methods of retroviral vector transduction and production for gene therapy. , 1994, Human gene therapy.